

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use Several Sheets if Necessary)

Application Number	10/816,465
Filing Date	April 1, 2004
First Named Inventor	MORENO-LÓPEZ
Art Unit	1653
Examiner Name	(NOT YET RECEIVED)
Attorney Docket No.	NHL-NP-45
IDS Mailing Date	July 15, 2004

Sheet 1 of 4

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code			
	AA	US -			
	AB	US -			
	AC	US -			
	AD	US -			
	AE	US -			
	AF	US -			
	AG	US -			
	AH	US -			
	AI	US -			
	AJ	US -			
	AK	US -			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation	
		Country Code-Number-Kind Code			YES	NO
	AL	EP 0 941 318	09/15/1999	Soft Gene GmbH	X	
	AM					
	AN					
	AO					
	AP					
	AQ					
	AR					
	AS					

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

AT	DNA-IMMUNE RESPONSES AFFECTED BY DIFFERENT INJECTION METHODS OF A MULTI-EPITOPE CHIMERIC DNA VACCINE OF PLASMODIUM FALCIPARUM, SHI ET AL., CHIN.J.MICROBIOL IMMUNOL, JANUARY 2001, VOL. 21, NO. 1, PP. 50-54 - XP-001154098
AU	DNA VACCINATION WITH LINEAR MINIMALISTIC (MIDGE) VECTORS CONFERS PROTECTION AGAINST LEISHMANIA MAJOR INFECTION IN MICE, LÓPEZ-FUERTE ET AL., VACCINE 21 (2002) PP. 247-257
AV	A REQUIREMENT FOR PHYSICAL LINKAGE BETWEEN DETERMINANTS RECOGNIZED BY HELPER MOLECULES AND CYTOTOXIC T CELL PRECURSORS IN THE INDUCTION OF CYTOTOXIC T CELL RESPONSES, KROWKA ET AL., J. OF IMMUNOLOGY, VOL. 136, NO. 10, MAY 15, 1986, PP.3561-3566
AW	INTRODUCTION TO THE MIDGE VECTOR TECHNOLOGY - XP-002252259

Examiner Signature

Date
Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use Several Sheets if Necessary)

Application Number	10/816,465
Filing Date	April 1, 2004
First Named Inventor	MORENO-LÓPEZ
Art Unit	1653
Examiner Name	(NOT YET RECEIVED)
Attorney Docket No.	NHL-NP-45
IDS Mailing Date	July 15, 2004

Sheet 2 of 4

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code			
	AA	US -			
	AB	US -			
	AC	US -			
	AD	US -			
	AE	US -			
	AF	US -			
	AG	US -			
	AH	US -			
	AI	US -			
	AJ	US -			
	AK	US -			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation	
		Country Code-Number-Kind Code			YES	NO
	AL					
	AM					
	AN					
	AO					
	AP					
	AQ					
	AR					
	AS					

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

AT'	THE SERUM MANNANOSE-BINDING PROTEIN AND THE MACROPHAGE MANNANOSE RECEPTOR ARE PATTERN RECOGNITION MOLECULES THAT LINK INNATE AND ADAPTIVE IMMUNITY, FRASER ET AL., SEMINARS IN IMMUNOLOGY, VOL. 10, 1998; PP.363-372
AU'	TAT PEPTIDE ON THE SURFACE OF LIPOSOMES AFFORDS THEIR EFFICIENT INTRACELLULAR DELIVERY EVEN AT LOW TEMPERATURE AND IN THE PRESENCE OF METABOLIC INHIBITORS, TORCHILIN ET AL., PNAS, JULY 17, 2001, VOL. 98, NO. 15, PP. 8786-8791
AV'	CELLULAR UPTAKE OF THE TAT PROTEIN FROM HUMAN IMMUNODEFICIENCY VIRUS, FRANKEL ET AL., CELL, VOL. 55, PP. 1189-1193, DECEMBER 23, 1988
AW'	DNA VACCINATION: ANTIGEN PRESENTATION AND THE INDUCTION OF IMMUNITY, SHEDLOCK ET AL., JOURNAL OF LEUKOCYTE BIOLOGY, VOL. 68, DECEMBER 2000, PP. 793-806

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use Several Sheets if Necessary)

Application Number	10/816,465
Filing Date	April 1, 2004
First Named Inventor	MORENO-LÓPEZ
Art Unit	1653
Examiner Name	(NOT YET RECEIVED)
Attorney Docket No.	NHL-NP-45
IDS Mailing Date	July 15, 2004

Sheet 3 of 4

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code			
	AA	US -			
	AB	US -			
	AC	US -			
	AD	US -			
	AE	US -			
	AF	US -			
	AG	US -			
	AH	US -			
	AI	US -			
	AJ	US -			
	AK	US -			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation	
		Country Code-Number-Kind Code			YES	NO
	AL					
	AM					
	AN					
	AO					
	AP					
	AQ					
	AR					
	AS					

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

AT"	IN VIVO PROTEIN TRANSDUCTION: INTRACELLULAR DELIVERY OF BIOLOGICALLY ACTIVE PROTEINS, COMPOUNDS AND DNA, SCHWARZE ET AL., TIPS - FEBRUARY 2000 (VOL. 21) PP. 45-48
AU"	INDUCTION OF NUCLEAR TRANSPORT WITH A SYNTHETIC PEPTIDE HOMOLOGOUS TO THE SV40 T ANTIGEN TRANSPORT SIGNAL, LANFORD ET AL., CELL, VOL. 46, PP. 575-582, AUGUST 15, 1986
AV"	PROTECTIVE IMMUNE RESPONSE AGAINST CUTANEOUS LEISHMANIASIS BY PRIME/BOOSTER IMMUNIZATION REGIMENS WITH VACCINIA VIRUS RECOMBINANTS EXPRESSING LEISHMANIA INFANTUM P36/LACK AND IL-12 IN COMBINATION WITH PURIFIED-p36, GONZALO ET AL., MICROBES AND INFECTION, 3, 2001, PP. 701-711
AW"	ROUTES OF PLASMID DNA VACCINATION THAT PRIME MURINE HUMORAL AND CELLULAR IMMUNE RESPONSES, BÖHM ET AL., VACCINE, VOL. 16, NO. 9/10, PP. 949-954, 1998

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use Several Sheets if Necessary)

Application Number	10/816,465
Filing Date	April 1, 2004
First Named Inventor	MORENO-LÓPEZ
Art Unit	1653
Examiner Name	(NOT YET RECEIVED)
Attorney Docket No.	NHL-NP-45
IDS Mailing Date	July 15, 2004

Sheet 4 of 4

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code			
	AA	US -			
	AB	US -			
	AC	US -			
	AD	US -			
	AE	US -			
	AF	US -			
	AG	US -			
	AH	US -			
	AI	US -			
	AJ	US -			
	AK	US -			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation	
		Country Code-Number-Kind Code			YES	NO
	AL					
	AM					
	AN					
	AO					
	AP					
	AQ					
	AR					
	AS					

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

	AT'''	PRIMING OF IMMUNE RESPONSES TO HEPATITIS B SURFACE ANTIGEN WITH MINIMAL DNA EXPRESSION CONSTRUCTS MODIFIED WITH A NUCLEAR LOCALIZATION SIGNAL PEPTIDE, SCHIRMBECK ET AL., J MOL MED (2001) 79: PP. 343-350
	AU'''	ROUTE AND METHOD OF DELIVERY OF DNA VACCINE INFLUENCE IMMUNE RESPONSES IN MICE AND NON-HUMAN PRIMATES, McCLUSKIE ET AL., MOLECULAR MEDICINE 5: PP. 287-300, 1999 - XP002941186
	AV	
	AW	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.